HACKENSACK UNIVERSITY MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $110.1M
- Transactions
- 14,631
- Companies
- 40
- Average per transaction
- $7,524
Who reported the payments
| E.r. Squibb & Sons, L.L.C. | $14,596,494 |
| Merck | $11,576,578 |
| Incyte Corporation | $8,040,321 |
| Gilead | $7,692,832 |
| Bristol Myers Squibb | $6,121,226 |
| Pfizer | $4,899,001 |
| Seagen Inc. | $4,212,842 |
| Genentech, Inc. | $4,207,102 |
| Modernatx, Inc. | $3,210,898 |
| Daiichi Sankyo Inc. | $2,814,515 |
| AbbVie | $2,555,194 |
| Jazz Pharmaceuticals Inc. | $2,439,430 |
| Otsuka Pharmaceutical Co., Ltd. | $2,326,016 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,928,798 |
| Regeneron | $1,838,907 |
| AstraZeneca | $1,652,247 |
| Sanofi US Services Inc. | $1,618,296 |
| Janssen Research & Development, LLC | $1,597,149 |
| Genmab A/s | $1,476,567 |
| Taiho Oncology, Inc. | $1,428,438 |
| Amgen | $1,392,683 |
| Acerta Pharma LLC | $1,234,034 |
| Beigene, Ltd. | $1,145,585 |
| Servier Pharmaceuticals LLC | $1,124,767 |
| Celularity Inc. | $1,108,998 |
| Astrazeneca UK Limited | $1,005,254 |
| Boehringer Ingelheim | $898,767 |
| Sanofi | $859,160 |
| Abiomed | $837,552 |
| Genmab U.S., Inc. | $699,404 |
| Roche Products Limited | $669,516 |
| Beigene AUS Pty Ltd | $650,961 |
| Abbott | $591,653 |
| National Marrow Donor Program | $515,577 |
| Amicus Therapeutics, Inc. | $493,743 |
| Stryker | $464,041 |
| Eli Lilly | $455,641 |
| F. Hoffmann-la Roche AG | $410,059 |
| Travere Therapeutics, Inc. | $379,049 |
| Sumitomo Pharma America, Inc. | $346,508 |